Physician profile
Mark Edward Beamer
NPI 1053426346
$10,893.31
in general payments reported to CMS, 2019-2025
38 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $1,386 · 2021: $1,573 · 2022: $1,273 · 2023: $1,779 · 2024: $1,465 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979 · Long Term Medical Supply Or Device Loan: $9.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,978.68 |
| Long Term Medical Supply Or Device Loan | $9.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,959.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,672.30 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,311.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,011.55 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $607.45 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $530.97 | 2019-2025 | |
| Lilly USA, LLC | $461.60 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $398.65 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $335.62 | 2021-2025 | Freestyle Libre 2, Freestyle Insulinx |
| Janssen Pharmaceuticals, INC | $319.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $317.61 | 2019-2022 | |
| Corcept Therapeutics | $300.08 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.44 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $175.64 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $169.33 | 2022-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Beamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.